Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: US Court Hands Stratagene Victory in Patent Dispute Launched by Invitrogen

SAN FRANCISCO, Feb. 8 - Stratagene has declared legal victory in a patent dispute sparked by Invitrogen.

 

In a final judgment handed down on Jan. 31, the US District Court for the Western District of Texas said that Stratagene did not infringe on Invitrogen patents related to its competent cell products.

 

According to Stratagene, the dispute began when Invitrogen sued the La Jolla, Calif.-based company for allegedly infringing one of its patents, No. 4,981,797. Then, in August last year, Invitrogen voluntarily withdrew its allegations, made against Stratagene's electrocompetent cell and certain chemically competent cell products, Stratagene said.

 

Invitrogen's position further eroded that month when the District Court narrowed its interpretation of the '797 patent, Stratagene said. Following the court's recent decision, Invitrogen withdrew its remaining patent-infringement allegations.

 

"We still feel strongly that our patent holds... and we decided to continue to fight in appeals court," said Mary Cassoni, an Invitrogen spokesperson.

 

"This particular lawsuit doesn't have a lot of risk for us," said Cassoni. "If we lost, we wouldn't be collecting royalties from Stratagene that we believe we're due. This still doesn't affect our business."

 

Invitrogen has foreign patents connected with the competent cell technology that is may use to persue additional litigation, added Cassoni. 

 

Competent cells, at the heart of the dispute, contain cell walls that have been manipulated to let them absorb various DNA in order to facilitate cloning projects. Stratagene creates various types of competent cell strains.

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.